MX9205155A - Derivados heterociclicos n-substituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene. - Google Patents

Derivados heterociclicos n-substituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Info

Publication number
MX9205155A
MX9205155A MX9205155A MX9205155A MX9205155A MX 9205155 A MX9205155 A MX 9205155A MX 9205155 A MX9205155 A MX 9205155A MX 9205155 A MX9205155 A MX 9205155A MX 9205155 A MX9205155 A MX 9205155A
Authority
MX
Mexico
Prior art keywords
procedure
preparation
pharmaceutical composition
composition containing
substituted hetero
Prior art date
Application number
MX9205155A
Other languages
English (en)
Spanish (es)
Inventor
Pierre Perreaut
Claude Muneaux
Yvette Muneaux
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Publication of MX9205155A publication Critical patent/MX9205155A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX9205155A 1991-09-10 1992-09-09 Derivados heterociclicos n-substituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene. MX9205155A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9111161A FR2681067B1 (fr) 1991-09-10 1991-09-10 Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
MX9205155A true MX9205155A (es) 1993-03-01

Family

ID=9416798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205155A MX9205155A (es) 1991-09-10 1992-09-09 Derivados heterociclicos n-substituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Country Status (19)

Country Link
EP (1) EP0532410A1 (enExample)
JP (1) JPH05213894A (enExample)
KR (1) KR930006008A (enExample)
AU (1) AU661017B2 (enExample)
CA (1) CA2077967A1 (enExample)
CZ (1) CZ275992A3 (enExample)
FR (1) FR2681067B1 (enExample)
HU (1) HUT63616A (enExample)
IL (1) IL103116A (enExample)
LT (1) LT3148B (enExample)
LV (1) LV10255B (enExample)
MX (1) MX9205155A (enExample)
MY (1) MY108089A (enExample)
NO (1) NO180678C (enExample)
NZ (1) NZ244258A (enExample)
PL (1) PL171524B1 (enExample)
RU (1) RU2107062C1 (enExample)
TW (1) TW218871B (enExample)
ZA (1) ZA926899B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131021T2 (de) * 1990-12-14 1999-08-12 Smithkline Beecham Corp., Philadelphia, Pa. 19101 Angiotensin-ii-rezeptor blockierende zusammensetzungen
US5484939A (en) * 1993-03-12 1996-01-16 Lonza Ltd. 2-substituted 5-chlorimidazoles
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
HU218681B (hu) * 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
HU218680B (hu) 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro[4,4]non-1-én-4-on-származékok előállítására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH539640A (de) 1970-05-29 1973-07-31 Agripat Sa Verfahren zur Herstellung neuer, herbizid wirksamer s-Triazine und deren Verwendung zur Bekämpfung von Unkräutern
US4017510A (en) 1975-11-12 1977-04-12 American Cyanamid Company Imidazoisoindolediones and the use thereof as herbicidal agents
DE3545597A1 (de) * 1985-12-21 1987-07-02 Celamerck Gmbh & Co Kg Neue herbizid wirksame imidazolinone
EP0303863A3 (en) * 1987-08-17 1991-10-23 American Cyanamid Company Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
JP2004247578A (ja) 2003-02-14 2004-09-02 Kawasaki Microelectronics Kk 半導体装置および半導体装置の製造方法

Also Published As

Publication number Publication date
TW218871B (enExample) 1994-01-11
HU9202889D0 (en) 1992-11-30
IL103116A0 (en) 1993-02-21
AU661017B2 (en) 1995-07-13
NO923509D0 (no) 1992-09-09
CA2077967A1 (en) 1993-03-11
HUT63616A (en) 1993-09-28
LV10255A (lv) 1994-10-20
LTIP119A (en) 1994-07-15
LV10255B (en) 1995-04-20
NZ244258A (en) 1996-10-28
FR2681067A1 (fr) 1993-03-12
NO180678C (no) 1997-05-28
PL171524B1 (pl) 1997-05-30
MY108089A (en) 1996-08-15
NO180678B (no) 1997-02-17
NO923509L (no) 1993-03-11
RU2107062C1 (ru) 1998-03-20
FR2681067B1 (fr) 1993-12-17
KR930006008A (ko) 1993-04-20
IL103116A (en) 1998-04-05
JPH05213894A (ja) 1993-08-24
LT3148B (en) 1995-01-31
CZ275992A3 (en) 1993-03-17
ZA926899B (en) 1993-03-16
AU2286892A (en) 1993-03-11
EP0532410A1 (fr) 1993-03-17
PL295874A1 (en) 1993-04-19

Similar Documents

Publication Publication Date Title
MX9205155A (es) Derivados heterociclicos n-substituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9205280A (es) Derivados de benzanilida, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9202619A (es) Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene.
FI942913L (fi) Isatiinijohdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
MX9102501A (es) Derivados de metano sulfonamida, composiciones farderivados de metanosulfonamida, composiciones farmaceuticas que los contienen y procedimiento para smaceuticas que los contienen y procedimiento para u preparacion. su preparacion.
MX9100317A (es) Nuevos compuestos de beta-lactama,procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9200180A (es) DERIVADOS DE LA 5H-PIRROL (3,4-b) PIRAZINA OPTICAMENTE ACTIVOS, PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9204844A (es) Derivados de benzodioxano, procedimiento para su preparacion composiciones farmaceuticas que los contienen.
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
MX9201847A (es) Derivados heterociclicos de antiserotoninas, procedimiento para su preparacion y medicamentos que los contienen.
MX9202300A (es) Derivados de benzofurano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX14253A (es) Compuestos de amonio cuaternario, composiciones farmaceuticas que incluyen los compuestos y procedimiento para preparar los compuestos de amonio cuaternario.
MX9204395A (es) Derivados de 3-desoxi-manosamina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9102499A (es) Derivados de benzamida, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9207269A (es) Bencimidazoles substituidos, proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX9200996A (es) Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9101594A (es) Compuestos de indenoidol,procedimiento para su preparacion y composicion farmaceutica que los contiene
IT8648547A0 (it) Derivati di dicloroanilina,procedimento per prepararli e composizioni farmaceutiche che li contengono
MX9203732A (es) R-enentiomeros de compuestos de n-propargil-1-aminoindan, su preparacion y composiciones farmaceuticas que contienen los mismos.
FI931188A7 (fi) Uudet 17-b-estradiolijohdannaiset, niiden valmistusmenetelmät ja näitä lääkeaineita sisältävät yhdisteet
MX9203632A (es) Derivados de cicloalquiltiazol y composiciones farmaceuticas que los contienen.